Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Renzo Canetta"'
Autor:
H. Kim Lyerly, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, Hiroshi Katayama, Silvy Da Rocha Dias, Daniel McManus, Kathy Soltys, Zhimin Yang, Olufumilayo Olopade, Nancy Goodman, Greg Reaman, Thomas Gross
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-11 (2018)
Advances in genetic sequencing and other diagnostic technologies have enabled the use of precision medicine in clinical cancer care, as well as the development of novel therapies that are targeted to specific molecular drivers of cancer. Developing t
Externí odkaz:
https://doaj.org/article/46a7ce1f1bc64090b5009fbf969ef5cc
Autor:
Roberto Salgado, David B. Solit, David L. Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, Paul N. Span, Alison Bateman-House, Amr Makady, L. Bergmann, Sumimasa Nagai, Chris Smith, Mark Robson, Mary Savage, Emile Voest, Christopher Sweeney, Philippe Lambin, Marlene Thomas, Lyndsay Harris, Denis Lacombe, Chistophe Massard, Rene Bernards, Richard Sullivan, Sabine Tejpar, Nina Lukinova, Herbert K. Lyerly, Helen Moore, Malcolm A. Smith, Laura Yee, Ray DuBois, William C. Hahn, Pasi Janne, Cheryl L. Willman, David Rimm, Lothar Bergmann, Ian A. Cree, Priti Hegde, Shirley Hopper, Marc Robson, Magnus Ingelman-Sundberg, Gwen Nichols, Francois Maignen, Benjamin Besse, Rafal Swierzewski, Astrid Kiermaier, Christophe Massard, Michael Caliguri, Victor Velculescu, Paolo Foggi, Willem C. Hahn, Vassilis Golfinopoulos
Publikováno v:
European Journal of Cancer, 114, pp. 128-136
European Journal of Cancer, 114, 128-136
European Journal of Cancer, 114, 128-136. ELSEVIER SCI LTD
European Journal of Cancer, 114, 128-136
European Journal of Cancer, 114, 128-136. ELSEVIER SCI LTD
Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug Development meeting in Brussels to address the existing dichotomy between increasing calls f
Autor:
Gi Hyun Kim, Olufumilayo Olopade, H. Kim Lyerly, Daniel McManus, Greg Reaman, Sumimasa Nagai, Thomas G. Gross, Nancy Goodman, Jun Ren, Silvy Da Rocha Dias, Kathy Soltys, Tomohiro Yamaguchi, Zhimin Yang, Hiroshi Katayama, Renzo Canetta, Ken Hatogai
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-11 (2018)
Journal of Global Oncology
Journal of Global Oncology
Advances in genetic sequencing and other diagnostic technologies have enabled the use of precision medicine in clinical cancer care, as well as the development of novel therapies that are targeted to specific molecular drivers of cancer. Developing t
Publikováno v:
Pharmacology & Therapeutics. 148:132-153
The discovery and increased understanding of the complex interactions regulating the immune system have contributed to the pharmacologic activation of antitumor immunity. The activity of effector cells, such as T and NK cells, is regulated by an arra
Autor:
Scott A. Boerner, Renzo Canetta, Patricia LoRusso, John Hohneker, Erin Balogh, Sharyl J. Nass, John A. Wagner
Publikováno v:
Clinical Cancer Research. 18:6101-6109
Cancer cells contain multiple genetic changes in cell signaling pathways that drive abnormal cell survival, proliferation, invasion, and metastasis. Unfortunately, patients treated with single agents inhibiting only one of these pathways—even if sh
Autor:
David Berman, R. Humphrey, Ramy Ibrahim, Alan J. Korman, Renzo Canetta, Axel Hoos, Kevin M. Chin, Vafa Shahabi, Kald Abdallah
Publikováno v:
Seminars in Oncology. 37:533-546
Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-cell activity led to development of the fully human, monoclonal antibody ipilimumab to block CTLA-4 and potentiate antitumor T-cell responses. Animal studies
Autor:
Renzo Canetta
Publikováno v:
Journal of Medicine and the Person. 9:83-85
The practice of medicine is today, as in the past, influenced by clinical research, which represents the final conduit of preclinical and translational science in their application to the patient’s treatment. Since the patients and their diseases a
Publikováno v:
Anti-cancer drugs. 25(5)
Chemotherapy is the mainstay of treatment for numerous cancer types, but resistance to chemotherapy remains a major clinical issue and is one of the driving influences underlying the development of new anticancer medications. One of the most importan
Autor:
Robert Gray, Jeffrey S. Abrams, Lori E. Dodd, James H. Doroshow, Boris Freidlin, Renzo Canetta, William D. Bushnell, Edward L. Korn, Rajeshwari Sridhara, Wenjuan Gu
Publikováno v:
Clin Trials
Background Measurement error in time-to-event end points complicates interpretation of treatment effects in clinical trials. Non-differential measurement error is unlikely to produce large bias [1]. When error depends on treatment arm, bias is of gre
Autor:
TP Cooley, Renzo Canetta, Lee P. Schacter, Marcel Rozencweig, John S. Lambert, Raphael Dolin, Howard A. Liebman, JD Allan, Susan Kelley, Mohan Beltangady
Publikováno v:
Blood. 80:2969-2976
Myelosuppression is associated with human immunodeficiency virus (HIV) infection and may also be produced by agents used for the treatment of the disease or the treatment of its complications. Didanosine (ddl; 2′,3′-dideoxyinosine) is a newer pur